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Mesenteric artery complications during
angioplasty and stent placement for atherosclerotic
chronic mesenteric ischemia
Gustavo S. Oderich, MD, Tiziano Tallarita, MD, Peter Gloviczki, MD, Audra A. Duncan, MD,
Manju Kalra, MBBS, Sanjay Misra, MD, Stephen Cha, MS, and Thomas C. Bower, MD, Rochester, Minn
Objective: The purpose of this study was to describe the incidence, management, and outcomes of mesenteric artery
complications (MACs) during angioplasty and stent placement (MAS) for chronic mesenteric ischemia (CMI).
Methods: We retrospectively reviewed the clinical data of 156 patients treated with 173 MAS for CMI (1998-2010).
MACs were defined as procedure-related mesenteric artery dissection, stent dislodgement, embolization, thrombosis, or
perforation. End points were procedure-related morbidity and death.
Results: There were 113 women and 43 men (mean age, 73  14 years). Eleven patients (7%) developed 14 MACs,
including distal mesenteric embolization in six, branch perforation in three, dissection in two, stent dislodgement in two,
and stent thrombosis in one. Five patients required adjunctive endovascular procedures, including in two patients each,
catheter-directed thrombolysis or aspiration, retrieval of dislodged stents, and placement of additional stents for
dissection. Five patients (45%) required conversion to open repair: two required evacuation of mesenteric hematoma, two
required mesenteric revascularization, and one required bowel resection. There were four early deaths (2.5%) due to
mesenteric embolization or myocardial infarction in two patients each. Patients with MACs had higher rates of mortality
(18% vs 1.5%) and morbidity (64% vs 19%; P<.05) and a longer hospital length of stay (6.3 4.2 vs 1.6 1.2 days) than
those without MACs. Periprocedural use of antiplatelet therapy was associated with lower risk of distal embolization or
vessel thrombosis (odds ratio, 0.2; 95% confidence interval, 0.06-0.90). Patients treated by a large-profile system had a
trend toward more MACs (odds ratio, 1.8; 95% confidence interval, 0.7-26.5; P  .07).
Conclusions:MACs occurred in 7% of patients who underwent MAS for CMI and resulted in higher mortality, morbidity,
and longer hospital length of stay. Use of antiplatelet therapy reduced the risk of distal embolization or vessel thrombosis.
There was a trend toward more MACs in patients who underwent interventions performed with a large-profile system.
(J Vasc Surg 2012;55:1063-71.)
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“During the past decade, mesenteric artery stenting
(MAS) has surpassed open bypass as the most frequently
used method of revascularization to treat chronic mesen-
teric ischemia (CMI). Several centers have adopted an
endovascular-first approach, relegating open revasculariza-
tion to patients in whom stenting fails or whose anatomy is
unsuitable for it.1 In a recent review of national outcomes,
Schemerhorn et al1 reported a sevenfold increase in the
number of mesenteric interventions since 1988 and a re-
markable reduction in the mortality rate from 15% with
open bypass to 4% with endovascular treatment. A recent
systematic review of the best available evidence indicates
that MAS decreases morbidity and hospital length of stay
and has similar mortality and clinical efficacy but results in
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han open bypass.2
Endovascular interventions are potentially associated
ith risk of access site and arterial complications from
atheter and wire manipulation, balloon dilation, and
tent placement. In the mesenteric arteries, dissection,
hrombosis, embolization, or perforation may result in
owel ischemia or bleeding, necessitating additional
bail-out” maneuvers, including conversion to open re-
air. Most important, these complications can be fatal or
esult in significant morbidity and prolonged hospitaliza-
ion if not recognized immediately. This study describes
he incidence, management, and outcomes of mesenteric
rtery complications (MACs) during mesenteric angio-
lasty or stenting for CMI.
ETHODS
The study was approved by the Mayo Clinic Institu-
ional Review Board. The clinical data of all consecutive
atients treated with an index MAS procedure for athero-
clerotic CMI by a multidisciplinary group of vascular
urgeons and interventional radiologists between 1998 and
010 were entered into an institutional database (1998-
010). CMI was diagnosed in patients with symptom (any
r all of abdominal pain, postprandial abdominal pain,
food fear,” weight loss) duration 2 weeks and evidence
rom conventional angiography of high-grade stenosis or
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acute-on-CMI, vasculitides, median arcuate ligament syn-
drome, or those who had reinterventions for failed mesen-
teric interventions were excluded from the study.
MACs were defined as anatomic abnormalities that
resulted from angioplasty and stent placement, such as
dissection, embolization, thrombosis, perforation, and
stent dislodgement. Most MACs were identified imme-
diately, but we included in the analysis patients with
lesions diagnosed after the procedure because of symp-
toms that prompted conventional angiography, com-
puted tomography angiography (CTA), or abdominal
exploration. Patients with asymptomatic MACs that
were not identified by completion angiography were not
included in the review.
Lesion characteristics (length, diameter, and severity of
calcification) and degree of angulation of the superior
Table I. Demographics, cardiovascular risk factors, and m
angioplasty and stent placement for chronic mesenteric isch
Variablesa All patients
Fe
Large profile
Patients 156 (100) 67 (43)
Demographics
Age 73  14 73  13
Female 113 (72) 47 (70)
Male 43 (27) 20 (30)
Clinical presentation
Abdominal pain 147 (94) 64 (95)
Weight loss 126 (80) 53 (79)
Food fear 82 (52) 41 (61)
Nausea/vomiting 41 (26) 24 (36)
Diarrhea 38 (24) 24 (36)
Cardiovascular risk factors
Hypertension 134 (85) 53 (79)
Dyslipidemia 103 (66) 38 (57)
Coronary artery disease 100 (64) 42 (63)
Cigarette smoker 89 (57) 46 (69)
Myocardial infarction 56 (36) 4 (6)
Peripheral artery disease 67 (43) 28 (42)
COPD 47 (30) 18 (27)
Cerebrovascular disease 49 (31) 27 (40)
Chronic renal insufficiency 39 (25) 21 (31)
Baseline creatinine, mg/dL 1.2  1.1 1.2  0.6
Diabetes mellitus 36 (23) 18 (27)
Congestive heart failure 30 (19) 15 (22)
SVS score sum 9.7  6.0 9.5  6.4
Preadmission medications
Any antiplatelet therapy 98 (62) 40 (60)
ASA 89 (57) 37 (55)
Clopidogrel 21 (13) 7 (10)
ASA  clopidogrel 12 (8) 2 (3)
Warfarin 20 (13) 13 (19)
Antiplatelet  anticoagulation 32 (20) 14 (21)
Statins 67 (43) 18 (27)
-blockers 70 (45) 24 (36)
ACE inhibitor 73 (46) 25 (37)b
Diuretic 50 (32) 19 (28)
ACE, Angiotensin-converting enzyme; ASA, acetylsalicylic acid; COPD, ch
aCategoric variables are expressed as number (percentage) and continuous v
bGroups associated with the lower P value.mesenteric artery (SMA) were analyzed in the preproce- oural CTA whenever possible. The severity of calcification
as graded as mild (minimal or trivial), moderate (66% of
essel diameter), or severe (66% of the vessel diameter).
emographics, clinical characteristics, imaging, and oper-
tive data were obtained from the medical records. The
arly perioperative period was defined as the first 30 days or
ithin the hospital stay if 30 days. Patient morbidity was
efined as a medical or surgical complication after the
rocedure that was caused by MAS. Patient morbidity was
nalyzed to determine its relationship to the MAC.
Rescue treatment for MACs was individualized at the
iscretion of the treating physician. Clinical observation
as indicated for small lesions that were not considered to
e flow limiting and were not associated with thrombus,
owel ischemia, or active bleeding. Adjunctive endovascu-
ar interventions (angioplasty, stent placement, catheter-
irected thrombolysis or thrombus aspiration, and retrieval
l therapy in 156 patients treated by mesenteric
a
l
P
Brachial
Pmall profile Large profile Small profile
39 (25) 14 (9) 36 (23)
73  14 .7 73  13 75  10 .07
31 (79) .6 8 (57) 27 (75) .6
8 (20) .4 6 (43) 9 (25) .4
36 (92) .99 14 (100) 33 (92) .8
33 (85) .8 10 (71) 30 (83) .7
13 (33) .1 5 (36) 23 (64) .3
8 (20) .2 3 (21) 6 (17) .7
7 (18) .1 2 (14) 5 (14) .99
35 (90) .6 14 (100) 32 (89) .8
28 (72) .4 10 (71) 27 (75) .99
22 (56) .8 10 (71) 26 (72) .99
22 (56) .6 6 (43) 15 (42) .99
13 (33) .002 5 (36) 14 (39) .99
20 (51) .5 6 (43) 13 (36) .99
14 (36) .4 7 (50) 8 (22) .2
10 (26) .3 4 (29) 8 (22) .3
8 (20) .4 4 (29) 6 (17) .5
1.3  1.8 .7 1.1  0.4 1.0  0.8 .8
9 (23) .8 1 (7) 8 (22) .3
5 (13) .3 4 (29) 6 (17) .5
11.6  6.0 .07 7.6  4.2 8.9  5.0 .4
27 (69) .6 5 (36) 26 (72) .2
23 (59) .8 4 (29) 25 (69) .1
6 (15) .5 2 (14) 6 (17) .99
4 (10) .2 1 (7) 5 (14) .99
2 (5) .08 0 (0) 5 (14) .2
5 (13) .4 1 (7) 12 (33) .1
19 (49) .1 7 (50) 23 (64) .6
14 (36) .99 8 (57) 24 (67) .7
22 (56)b .2 8 (57) 18 (50) .8
16 (41) .3 7 (50) 8 (22) .2
obstructive pulmonary disease.
es as mean  standard deviation.edica
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with significant lesions.
Technical success was defined by residual stenosis
30% by completion angiography. Residual stenosis typi-
cally resulted from a recalcitrant lesion or dissection, or
both. Antiplatelet therapy included aspirin before the pro-
cedure, clopidogrel for 4 to 8 weeks after the procedure,
and aspirin thereafter. All patients received intravenous
heparin anticoagulation (80-100 U/kg) at the time of
mesenteric intervention.
Statistical analysis. Data were analyzed using Society
for Vascular Surgery (SVS) reporting standards.3 Primary
end points were procedure-related morbidity and mortal-
ity. Univariate and multivariate analyses were used to iden-
tify clinical, anatomic, and procedural factors associated
with MACs. Results are reported as median  standard
deviation, percentages, or odds ratio (OR) with the 95%
confidence interval (95% CI). The Pearson 2 or Fisher
exact test was used for analysis of categoric variables. Dif-
ferences between means were tested with two-sided t-test,
the Wilcoxon rank-sum test, or the Mann-Whitney test. A
value of P  .05 was used to determine statistical signifi-
cance.
RESULTS
The study evaluated 113 women and 43 men (mean
age, 72  13 years). The most common presenting symp-
tom (Table I) was abdominal pain, 147 (94%); weight loss,
126 (80%); “food fear,” 82 (52%); nausea or vomiting, or
both, 41 (26%); and diarrhea, 38 (24%). A total of 173
mesenteric vessels were treated (Table II) by angioplasty
alone (22 SMA, 10 celiac axis [CA], and three inferior
mesenteric arteries [IMA]) or angioplasty and stent place-
ment (94 SMA, 42 CA, and two IMA).
Femoral access was used in 106 patients (68%) and
brachial access in 50 (32%), including 34 patients who
underwent primary exposure and repair of the brachial
artery under local anesthesia. A large-profile system (0.035-
inch wire) was used in 81 patients (52%) to treat 94 vessels,
whereas interventions in 75 vessels (48%) were with a
small-profile system (0.014- or 0.018-inch). Of 106 pa-
tients treated by the transfemoral approach, 67 (64%) had
interventions with a large-profile system vs 39 (37%; P 
.01) with a small-profile system, whereas of 50 transbrachial
interventions, 36 (72%) were performed with small-profile
systems vs 14 (28%; P  .02) with a large-profile system.
Balloon-expandable stents were used to treat 134 lesions in
125 patients (98%), and self-expandable stents were used to
treat four lesions in three patients. Technical success was
achieved in 166 (96%) of the 173 vessels. Completion
angiography demonstrated no residual stenosis in 147 ves-
sels, residual stenosis 30% in 19, and residual stenosis
30% in seven.
MACs. Eleven patients (7%) developed 14MACs (Ta-
ble III,A and B). The incidence of MAC was 10% for SMA
interventions (12 of 117), 2% for CA (one of 52), 20% for
IMA (one of five), 9% for angioplasty alone (three of 35),
and 8% for MAS (11 of 139). iSix patients had embolization to distal branches (Fig
), which occurred along with proximal flow-limiting dis-
ection, stent dislodgement, or stent thrombosis in one
atient each. Three patients developed jejunal branch per-
orations, including one patient with a small contained
erforation associated with a small-profile system and two
atients with large mesenteric hematomas (Fig 2) associ-
ted with multiple exchanges of large-profile guidewires.
ne patient had isolated SMA dissection and another had
tent dislodgement without distal embolization. The two
atients with stent dislodgement had hand-mounted stents
laced through a transfemoral approach, with severe SMA
ngulation.
Rescue treatment. The complication was recognized
able II. Procedural details in 156 patients treated by
esenteric angioplasty and stent placement for chronic
esenteric ischemia
Variables
Mean  SD, or
patients/vessels
No. (%)
Target vessela
Length, mm 15  4.4
Diameter, mm 5.8  0.8
Superior mesenteric artery 116 (67)
Celiac artery 52 (30)
Inferior mesenteric artery 5 (3)
One vessel treated 125 (72)
Two vessels treated 24 (28)
Calcificationb
Absent/irrelevant 23 (13)
Moderate 19 (11)
Severe 56 (32)
Technical data
PTA with stenting 128/138 (80)
PTA alone 28/35 (20)
Stent/balloon, mm
Diameter 5.8  0.6
Length 20.8  8
Stent type
Balloon-expandable 125/134
Self-expandable 3/4 (2)
Embolic protection device 14 (9)
Femoral approach 106 (68)
Brachial approach 50 (33)
Profile
Large, 0.035-inch 81 (52)
Small, 0.018-inch 75 (48)
Femoral
 large profile 67 (43)
 small profile 39 (25)
Brachial
 small profile 36 (23)
 large profile 14 (9)
Residual stenosis
Absent 132 (85)
30% 16 (10)
30% 8 (5)
TA, Percutaneous transluminal angioplasty; SD, standard deviation.
Denominator is the number of vessels (n  173).
For only 88 patients/98 vessels was computed tomography/computed
omography angiography imaging available.mmediately in eight patients (73%), including five with
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c
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lodgement, or contained perforation, respectively. The small,
contained branch perforation spontaneously sealed on follow-up
angiography performed during the procedure and did not
Table III. A, Demographics, lesion characteristics, and pr
stent placement for chronic mesenteric ischemia
Pt Age Sex
Medical
therapy Lesion characteristics Appro
1 73 F ASA SMA occlusion, 15-mm
length, severe
calcification, SMA
angle 21°
Femo
2 85 F ASA CA high-grade stenosis,
14-mm length, severe
calcification, SMA
angle 30°
Femo
3 66 F None SMA high-grade
stenosis, 22-mm
length, severe
calcification, SMA
angle 26°
Femo
4 84 M CLOP SMA high-grade
stenosis, 35-mm
length, mild
calcification
Femo
5 69 F None SMA high-grade
stenosis, 15-mm
length, severe
calcification, SMA
angle 66°
Femo
6 68, F F CLOP SMA high-grade
stenosis, 14-mm
length, moderate
calcification, SMA
angle 15°
Femo
7 62, F F None IMA high-grade
stenosis, 9-mm
length, severe
calcification, IMA
angle 32°
Femo
8 58 F None SMA high-grade
stenosis, 15-mm
length, moderate
calcification, SMA
angle 21°
Brach
9 83 F CLOP, ASA SMA high-grade
stenosis, 23-mm
length, severe
calcification; SMA
angle 36°
Femo
10 77 M ASA SMA occlusion, 50-mm
length, moderate
calcification, SMA
angle 48°
Brach
11 80 F CLOP SMA high-grade
stenosis, 22-mm
length, mild
calcification, SMA
angle 23°
Brach
ASA, Acetylsalicylic acid;CA, celiac axis;CLOP, clopidogrel; F, female;GW, guiderequire treatment. The large mesenteric hematomas were eiagnosed in two patients at 12 and 27 hours after the
rocedure because of significant abdominal pain and de-
reasing hemoglobin, which prompted CTA (Fig 2). One
atient presented with abdominal pain and bowel isch-
ural details of 11 patients treated by angioplasty and
Procedure details
Mesenteric artery
complication
Multiple
exchanges GW profile and type Stent
Yes 0.035-inch stiff
hydrophilic GW,
stiff J-tip braided
GW
5-  12-mm
balloon
Embolization
No 0.035-inch stiff
angled
hydrophilic GW,
0.014-inch stiff
braided GW
6  17 mm Embolization
No 0.035-inch
hydrophilic GW,
0.035-inch
straight braided
GW
6  27 mm Dissection,
embolization
Yes 0.035-inch angled
hydrophilic GW
6  15 mm Stent
thrombosis,
embolization
Yes 0.035-inch stiff
hydrophilic GW,
straight braided
GW
6  27 mm
(hand
mounted)
Stent
dislodgement,
embolization
Yes 0.035-inch stiff
angled GW inch
system
5  17 mm Perforation
Yes 0.035-inch J-tip
braided GW,
0.018-inch
straight-tip
braided GW
5-  20-mm
balloon
Embolization
No 0.035-inch stiff
angled
hydrophilic GW
4-  18-mm
balloon
Perforation
Yes 0.035-inch straight
braided GW
6  27 mm
(hand
mounted)
Stent
dislodgement
No 0.035-inch straight
braided GW
6  17 mm Dissection
No 0.014-inch
hydrophilic
straight GW
6  18 mm Perforation
MA, inferior mesenteric artery;M,male; SMA, superior mesenteric artery.oced
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angiography.
Five patients underwent adjunctive endovascular in-
terventions. Two patients underwent placement of a
second stent, which successfully resolved dissection flaps.
Two dislodged stents were retrieved using a snare and
deployed in a neutral position within the iliac artery,
followed by successful repeat stenting of the SMA. Two
patients with distal embolization underwent catheter-
directed thrombolysis and thrombus aspiration (Fig 1).
Five patients required conversion to open surgical re-
pair, including after failed endovascular treatment in one.
The two patients with large mesenteric hematomas were
treated by abdominal exploration, evacuation of the hema-
toma, and hemostasis. One patient with stent thrombosis
underwent removal of the stent, thromboendarterectomy,
and patch angioplasty. One patient with sigmoid ischemia
from distal embolism required segmental colectomy and
mesenteric bypass, and another patient with distal embo-
lism required bowel resection without revascularization.
Mortality. There were four procedure-related deaths
(2.5%). Early mortality was 18% (two of 11) in patients with
MACs compared with 1.4% in those who had no MACs
(two of 145; P  .001). Two patients with distal emboli-
zation died ofmultiorgan system failure (MOSF) 11 and 58
days later, despite abdominal exploration and revasculariza-
tion. Two patients with pre-existing ischemic cardiomyop-
athy died of myocardial infarction. Multivariate analysis
found no independent predictors for death.
Morbidity. Thirty-four patients (15%) presented
with 46 postprocedural complications (Table IV). Seven
Table III. B, Treatment and outcomes in 11 patients who
angioplasty and stent placement for chronic mesenteric isch
Pt
Mesenteric artery
complication
Rescue treatment
Timing Intervention
1 Embolization Immediate Ao-SMA bypass, bowel
resection
2 Embolization Immediate t-PA  catheter aspiration
3 Dissection,
embolization
Immediate Stent placement
4 Stent thrombosis,
embolization
Immediate Thromboendarterectomy,
removal, patch angiopla
5 Stent dislodgement,
embolization
Immediate Local t-PA, catheter aspira
re-stenting
6 Perforation Delayed Surgical evacuation, ligati
bleeding branch
7 Embolization Delayed Bowel resection
8 Perforation Delayed Surgical evacuation, ligati
bleeding branch
9 Stent dislodgement Immediate Restenting
10 Dissection Immediate t-PA  stenting
11 Perforation Immediate Sealed spontaneously on f
up angiography
Ao, Aorta; LOS, length of stay; MOSF, multiorgan system failure; SMA, suppatients (64%) with MACs developed additional compli- 9ations compared with 28 (19%) of those who did not
ave MACs during the intervention (P  .01). The most
ommon complications were access-related problems in
1 patients, renal insufficiency in seven (dialysis-depen-
ent in one), myocardial infarction in four, gastrointes-
inal bleeding in two, and lower extremity embolization
n one. Eight access-site complications occurred in six
atients (6%) who had transfemoral interventions, in-
luding five pseudoaneurysms, two infections, and one
erve injury. Three patients required surgical evacuation
f hematoma. Eight access-site problems developed
mong five patients treated by a transbrachial approach
10%), all occurring among 16 patients (31%) who had
ercutaneous approach. Access-related problems in-
luded pseudoaneurysm in three patients and arterial
hrombosis, arteriovenous fistula, or swelling in one
ach. Of these, three patients underwent hematomas and
epair of pseudoaneurysms, including two patients with
emporary neuropraxia of the median nerve.
Hospital length of stay was significantly longer (P 
05) among patients who developed MACs (6.3  4.2 vs
.6  1.2 days) and among those who had postprocedural
omplications (12  5 vs 1  2 days). Factors associated
ith higher rates of postprocedural complications by uni-
ariate analysis (OR and 95% CI) were female sex, 3.4
1.3-9.0; P .01); diabetes, 3.0 (0.97-9.2; P .06); renal
nsufficiency, 2.9 (0.9-9.1; P  .07); chronic obstructive
ulmonary disease, 2.9 (0.9-8.8; P .07); and MACs, 3.8
0.8-18.4; P  .1). Female sex was the only independent
actor associated with a higher morbidity rate (OR, 2.9;
eloped mesenteric artery complications during
a
Early outcome Late outcome
Resolution
Post-MAS
complication
LOS
(days)
Follow-up
(months) Status
Yes Acute renal
failure
18 None . . .
Yes None 5 None . . .
Yes Acute renal
failure
7 23 Restenosis
Yes Acute renal
failure
21 3 Patent
No Bowel resection,
MOSF, death
11 . . . . . .
Yes No further
complications
16 4 Patent
No MOSF, death 58 . . .
Yes No further
complications
12 21 Patent
Yes No further
complications
2 None . . .
Yes Acute renal
failure
4 1 Patent
- Yes No further
complications
2 3 Patent
esenteric artery; t-PA, tissue, plasminogen activator.dev
emi
stent
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tion,
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(OR, 4.09; 95% CI, 0.8-70.0; P  .2).
Predictors of MACs. Patients whose interventions
were performed with a large-profile system had a 12%
rate of MACs compared with 4% in those who underwent
procedures with a small-profile system (OR, 1.8; 95% CI,
0.7-26.5; P  .07). Patients treated by a large-profile
system sustained more dissections, embolizations, and
perforations, but differences did not reach statistical
significance (Table IV). MACs occurred in eight patients
(8.4%) treated through a femoral approach (seven of 68
for large-profile vs one of 39 for small-profile system; P
.09) and in three (6%) who had transbrachial procedures
(two of 14 for large-profile vs one of 36 for small-profile
system; P  .5). Use of antiplatelet therapy was associ-
ated with lower rates of distal embolization or vessel
thrombosis (OR, 0.2; 95% CI, 0.06-0.90; P  .03) by
univariate model. However, there were no independent
factors for MACs by multivariate analysis.
DISCUSSION
Endovascular treatment has several short-term advan-
Fig 1. An 85-year-old woman presented with chronic a
the celiac axis and superior mesenteric artery (SMA). A
complicated by distal embolization (white arrow), which
ysis and catheter aspiration with an Export aspiration cath
D, Completion angiography showed widely patent SMAtages compared with open surgical bypass in patients with rMI.1,2,4-12 However, despite its minimally invasive ap-
roach, angioplasty and stent placement carries a predict-
ble risk of morbidity and mortality. This study indicates
hat the occurrence of anatomic complications during cath-
ter manipulations and stent placement significantly in-
reases the risk of death (18%) and morbidity (54%) and
lso prolongs hospitalization.
Mortality rates are 0% to 10% in contemporary reports
f MAS.6,13-17 The most common causes of death in these
eports are myocardial infarction andMOSF, which is often
aused by bowel ischemia from distal embolization, dissec-
ion, or stent thrombosis. The Cleveland Clinic group
eported that three of their five deaths (60%) resulted from
istal embolism. Similar to that report, two of our four
eaths (50%) occurred in patients with distal embolization
esulting in bowel ischemia and MOSF. Therefore, proce-
ure planning, case selection, and use of meticulous tech-
ique are likely to be important factors that will reduce rates
f MACs and therefore have a positive effect on morbidity
nd mortality after these interventions.
We attempted to identify that factors that predisposed
atients to develop MAC. Unfortunately, because of the
inal pain and weight loss for 3 months and occlusion of
B, Successful recanalization of an occluded SMA was
C) successfully salvaged by catheter-directed thrombol-
Medtronic, Minneapolis, Minn) over a 0.014-inch wire.
a small, non–flow-limiting dissection flap (black arrow).bdom
and
was (
eter (etrospective design and small number of patients, we were
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learning curve, and technical difficulties encountered dur-
ing the procedure. However, we found a trend toward
more MACs among patients treated by larger-profile de-
vices, which makes intuitive sense given that these devices
require larger delivery systems and stiffer guidewires to
provide enough support. Some of the complications noted
in the study, such as dissections and branch perforations,
may occur more frequently in patients treated by larger-
profile devices, particularly if multiple exchanges are neces-
sary to overcome acute angulation. Another important
Fig 2. A, Mesenteric artery stenting performed throug
perforation (white arrow). The correct location to position t
mesenteric artery (A, black curved arrow and C) and not wobservation is to visualize the tip of the guidewire in the wain trunk of the SMA instead of within a small jejunal
ranch, which is more prone to dissection or perforation.
We also noted that the risk of embolization and throm-
osis was reduced by antiplatelet therapy started before the
ntervention. Finally, stent dislodgement, which occurred
n two patients treated by hand-mounted stents, has not
een a problem since premounted stents became available.
owever, this complication can occur with covered stents
r in patients with recalcitrant lesions that are prone to
watermelon seed” the stent during deployment.
Endovascular technology evolved during the last decade
femoral approach was complicated by (B) side branch
idewire should be ideally in the main trunk of the superior
jejunal branches (A, straight black arrow and C).h the
he guith the introduction of a wide range of smaller-profile
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April 20121070 Oderich et aldevices, rapid-exchange systems, hydrophilic sheaths,
guide catheters, premounted stents, and embolic protec-
tion devices. Although we were not able to evaluate the
effect of each one of these technologic improvements, there
are important lessons from our initial experience.
The ideal approach (femoral vs brachial) is controver-
sial and somewhat dependent on the ability of the treating
physician to surgically repair the brachial artery. Nonethe-
less, we found that the brachial approach offers excellent
access in patients with acute angles at the vessel origin,
occlusions, or long lesions. The mesenteric arteries are
easier to catheterize from above, and amore favorable angle
decreases the need to use stiff guidewires and avoids mul-
tiple catheter exchanges that may be necessary because of
access difficulties that are encountered from the femoral
approach. Nevertheless, brachial punctures are more prone
to access-related complications, including potentially dis-
abling neuropraxia of the median nerve, as noted in this
study. Therefore, we have more often used surgical expo-
sure and repair of the brachial artery under local anesthesia.
Another alternative to the brachial approach, which has
been widely used for cardiac interventions, is radial artery
Table IV. Periprocedural mortality and morbidity among
placement for chronic mesenteric ischemia
Variable
Femoral, No. (%)
Large profile
(n  67)
Small profile
(n  39)
Mortality 1 (1.5) 0 (0)a
Any complications 25 (37)a 6 (15)a
Cardiac
Myocardial infarction 1 (1.5) 0 (0)
Cardiac arrest 1 (1.5) 0 (0)
Respiratory
Intubation 72 hours 1 (1.5) 0 (0)a
Pneumonia 0 (0)a 0 (0)
Renal
Renal failure 4 (6)a 1 (2.6)
Dialysis 1 (1.5)a 0 (0)a
Others
Upper GI bleeding 1 (1.5) 1 (2.6)a
Limb embolism 1 (1.5)a 0 (0)
Cerebral ischemia 0 (0) 0 (0)
Any access-site complication 6 (9) 2 (5.6)
Hematoma 0 (0) 0 (0)
Thrombosis 0 (0) 0 (0)
Arteriovenous fistula 0 (0) 0 (0)
Pseudoaneurysm 4 (6)a 1 (2.6)
Nerve injury 0 (0)a 1 (2.6)
Wound infection 2 (3)a 0 (0)a
Arm swelling 0 (0)a 0 (0)
Any MAC 9 (13.4)a 2 (5.6)
Mesenteric embolism 5 (7.5)a 1 (2.6)
Vessel perforation 0 (0)a 1 (2.6)
Dissection 1 (1.5) 0 (0)a
Dislodging of stent 2 (3)a 0 (0)a
Stent thrombosis 1 (1.5)a 0 (0)a
GI, Gastrointestinal; MAC, mesenteric artery complication.
aIndicates variables compared and the P value.access. tThe use a small-profile (0.014- or 0.018-inch) system
as several advantages, including smaller delivery system,
apid exchange, and potentially less traumatic guidewires
nd stents. In general, guidewires with a braided or plati-
um tip are less traumatic than those with hydrophilic tips,
ut the latter are ideal to cross occlusions or difficult
tenosis. The tip of the guidewire should be visualized to
void inadvertent perforation or dissections. Finally, we
ave used balloon-expandable stents in nearly all cases
ecause of the advantages of precise deployment and
reater radial force, key elements when treating ostial le-
ions such as those involving the mesenteric arteries. None-
heless, self-expandable stents are useful to treat those
onger lesions that extend over tortuous or angulated seg-
ents of the mesenteric vessels.
The use of embolic protection devices during MAS
emains controversial. However, these devices should be
onsidered as part of the armamentarium in selected cases,
iven that distal embolization is an important cause of
eath in many reports. We previously reviewed the inci-
ence of distal embolization in 85 consecutive patients
reated by SMA stent placement without embolic protec-
patients treated by mesenteric angioplasty and stent
Brachial, No. (%)
Total, No. (%)
(N  156) P
Large profile
(n  14)
Small profile
(n  36)
2 (14)a 1 (2.8) 4 (2.5) .08a
4 (28) 12 (33) 46 (30) .05a
0 (0)a 2 (5.6)a 3 (1.9) .2a
0 (0) 0 (0) 1 (0.6) .99a
0 (0) 0 (0) 1 (0.6) .99a
0 (0) 1 (2.8)a 1 (0.6) .3a
1 (7) 0 (0)a 6 (3.8) .3a
0 (0) 0 (0) 1 (0.6) .99a
0 (0)a 0 (0) 2 (1.3) .99a
0 (0) 0 (0)a 1 (1.3) .99a
1 (7)a 0 (0)a 1 (0.6) .3a
0 (0)a 8 (22)a 16 (10.2) .2a
0 (0)a 1 (2.8)a 1 (0.6) .5a
0 (0)a 1 (2.8)a 1 (0.6) .5a
0 (0)a 1 (2.8)a 1 (0.6) .5a
0 (0)a 2 (5.6) 7 (4.5) .99a
0 (0) 2 (5.6)a 3 (1.9) .1a
0 (0) 0 (0) 2 (1.3) .5a
0 (0) 1 (2.8)a 1 (0.6) .5a
2 (14) 1 (2.8)a 14 (9) .2a
0 (0) 0 (0)a 6 (3.8) .2a
1 (7)a 1 (2.8) 3 (1.9) .5a
1 (7)a 0 (0) 2 (1.3) .3a
0 (0) 0 (0) 2 (1.3) .5a
0 (0) 0 (0) 1 (0.6) .99a156ion and found angiographic confirmation of emboli in 8%
R1
1
1
1
1
1
1
1
1
1
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the only two procedure-related deaths in the entire cohort.
Factors associated with higher rates of distal embolization
were mesenteric occlusion, severe calcification, and lesion
length30 mm.18 Since that 2009 report, we have started
using embolic protection devices selectively in patients with
at least one of the anatomic characteristics mentioned
above. In a recent review of our first 14 patients so treated,
nine (65%) had macroscopic debris in the filter basket, and
none had distal embolization on completion angiography,
compared with a 5% rate of embolization among 43 pa-
tients treated without embolic protection during the same
period.19
Although this study is novel because it addressed the
incidence, predictive factors, management, and outcomes
of MACs, several shortcomings need to be discussed. We
were not able to determine the individual factors that
affected choice of the technique and device selection or the
effect of learning curve. In addition, because angiographic
studies were reviewed retrospectively and invasive imaging
was not obtained in patients who had an uneventful recov-
ery, our study likely underreported the rates of MACs.
Furthermore, the small number of patients with events
limits our ability to analyze predictive factors for MACs
using a multivariate model.
CONCLUSIONS
MACs occurred in 7% of patients undergoing MAS
for CMI and resulted in higher morbidity and mortality
rates and a longer hospital stay. The use of larger-profile
devices was associated with a trend toward more MACs,
whereas the use of antiplatelet therapy during the proce-
dure reduced the risk of distal embolization or vessel
thrombosis. Our technique has evolved to where now we
prefer to use the brachial approach in patients with an
angulated SMA origin, occlusions, or difficult lesions.
However, we recognize that brachial punctures are asso-
ciated with the potential risk of access-related problems,
and currently, we frequently perform surgical repair of
the puncture site with a small incision. Finally, improve-
ments in patient selection, medical therapy, and endo-
vascular techniques, including the use of smaller-profile
systems and selective embolic protection, are likely to
reduce rates of MACs.
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